Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Alessandro Tomelleri and Corrado Campochiaro.
Alessandro Tomelleri
Connection Strength
3.655
Corrado Campochiaro
  1. Response to 'Correspondence on 'Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric survey'' by Montero et al. Ann Rheum Dis. 2021 Jul 02.
    View in: PubMed
    Score: 0.954
  2. Response to: 'Correspondence on 'Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric survey' by Comarmond et al. Ann Rheum Dis. 2020 Nov 12.
    View in: PubMed
    Score: 0.913
  3. Efficacy and Safety of Methotrexate for the Treatment of Autoimmune Virus-Negative Myocarditis: A Case Series. J Clin Rheumatol. 2021 Jun 01; 27(4):e143-e146.
    View in: PubMed
    Score: 0.237
  4. Potential acceptance of COVID-19 vaccine in rheumatological patients: a monocentric comparative survey. Ann Rheum Dis. 2021 01 28.
    View in: PubMed
    Score: 0.232
  5. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med. 2020 06; 76:43-49.
    View in: PubMed
    Score: 0.221
  6. Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey. Ann Rheum Dis. 2020 09; 79(9):1252-1253.
    View in: PubMed
    Score: 0.220
  7. Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series. Eur J Intern Med. 2018 11; 57:e11-e12.
    View in: PubMed
    Score: 0.195
  8. Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim-Chester Disease. Front Immunol. 2018; 9:1233.
    View in: PubMed
    Score: 0.193
  9. Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation. Front Immunol. 2021; 12:675678.
    View in: PubMed
    Score: 0.059
  10. Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. Lancet Rheumatol. 2021 Apr; 3(4):e253-e261.
    View in: PubMed
    Score: 0.058
  11. Living with fibromyalgia during the COVID-19 pandemic: mixed effects of prolonged lockdown on the well-being of patients. Rheumatology (Oxford). 2021 01 05; 60(1):465-467.
    View in: PubMed
    Score: 0.058
  12. Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic. Front Pharmacol. 2020; 11:598308.
    View in: PubMed
    Score: 0.057
  13. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. Lancet Rheumatol. 2020 Aug; 2(8):e465-e473.
    View in: PubMed
    Score: 0.055
  14. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020 Jun; 2(6):e325-e331.
    View in: PubMed
    Score: 0.055
  15. Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience. Rheumatology (Oxford). 2020 01 01; 59(1):171-175.
    View in: PubMed
    Score: 0.054
  16. Correction to: Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease. Arthritis Res Ther. 2019 Feb 25; 21(1):69.
    View in: PubMed
    Score: 0.051
  17. Tocilizumab in patients with multisystem Erdheim-Chester disease. Oncoimmunology. 2017; 6(6):e1318237.
    View in: PubMed
    Score: 0.045
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.